Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections.

Authors: Monath TP,Craven RB,Adjukiewicz A,Germain M,Francy DB,Ferrara L,Samba EM,N'Jie H,Cham K,Fitzgerald SA,Crippen PH,Simpson DI,Bowen ET,Fabiyi A,Salaun JJ,
Address:
Journal: Am J Trop Med Hyg.


Publication: 1980 Sep;29(5):912-28.

abstract

An epidemic of Yellow fever (YF) occurred in the Gambia between May 1978 and January 1979. Retrospective case-finding methods and active surveillance led to the identification of 271 clinically suspected cases. A confirmatory or presumptive laboratory diagnosis was established in 94 cases. The earliest serologically documented case occurred in June 1978, at the extreme east of the Gambia. Small numbers of cases occurred in August and September. The epidemic peaked in October, and cases continued to occur at a diminishing rate through January, when a mass vaccination campaign was completed. The outbreak was largely confined to the eastern half of the country (MacCarthy Island and Upper River Divisions). In nine survey villages in this area (total population 1,531) the attack rate was 2.6--4.4%, with a mortality rate of 0.8%, and a case fatality rate of 19.4%. If these villages are representative of the total affected region, there may have been as many as 8,400 cases and 1,600 deaths during the outbreak. The disease incidence was highest in the 0- to 9-year age group (6.7%) and decreased with advancing age to 1.7% in persons over 40 years. Overall, 32.6% of survey village inhabitants had YF complement-fixing (CF) antibodies. The prevalence of antibody patterns indicating primary YF infection decreased with age, in concert with disease incidence. The overall inapparent:apparent infection ratio was 12:1. In persons with serological responses indicating flaviviral superinfection, the inapparent:apparent infection ratio was 10 times higher than in persons with primary YF infection. Sylvatic vectors of YF virus, principally Aedes furcifer-taylori and Ae. luteocephalus are believed to have been responsible for transmission, at least at the beginning of the outbreak. Eighty-four percent of wild monkeys shot in January 1979 had YF neutralizing antibodies, and 32% had CF antibodies. Domestic Aedes aegypti were absent or present at very low indices in many severely affected villages (see companion paper). In January, however, aegypti-borne YF 2.5 months into the dry season was documented by isolation of YF virus from a sick man and from this vector species in the absence of sylvatic vectors. Thus, in villages where the classical urban vector was abundant, interhuman transmission by Ae. aegypti occurred and continued into the dry season. A mass vaccination campaign, begun in December, was completed on 25 January, with over 95% coverage of the Gambian population. A seroconversion rate of 93% was determined in a group of vaccinees. This outbreak emphasizes the continuing public health importance of YF in West Africa and points out the need for inclusion of 17D YF vaccination in future programs of multiple immunication.



Related Articles
Yellow fever in the Gambia, 1978--1979: entomological aspects and epidemiological correlations.
Am J Trop Med Hyg. 1980
Yellow fever in the Gambia, 1978--1979: entomological aspects and epidemiological correlations.
Germain M, Francy DB, Monath TP, Ferrara L, Bryan J, Salaun JJ, Heme G, Renaudet J, Adam C, Digoutte JP. Am J Trop Med Hyg. 1980 Sep; 29(5):929-40.
Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
Am J Trop Med Hyg. 1980
Limitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areas.
Monath TP, Craven RB, Muth DJ, Trautt CJ, Calisher CH, Fitzgerald SA. Am J Trop Med Hyg. 1980 Jul; 29(4):624-34.
Re-emergence of yellow fever in Senegal in 1995.
Am J Trop Med Hyg. 1998
Re-emergence of yellow fever in Senegal in 1995.
Thonnon J, Fontenille D, Tall A, Diallo M, Renaudineau Y, Baudez B, Raphenon G. Am J Trop Med Hyg. 1998 Jul; 59(1):108-14.
Review [The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus].
Bull Soc Pathol Exot. 1996
Review [The risk of urban yellow fever outbreaks in Brazil by dengue vectors. Aedes aegypti and Aedes albopictus].
Mondet B, da Rosa AP, Vasconcelos PF. Bull Soc Pathol Exot. 1996; 89(2):107-13; discussion 114.
Review Yellow fever: the recurring plague.
Crit Rev Clin Lab Sci. 2004
Review Yellow fever: the recurring plague.
Tomori O. Crit Rev Clin Lab Sci. 2004; 41(4):391-427.
Assessing yellow Fever risk in the ecuadorian Amazon.
J Glob Infect Dis. 2009
Assessing yellow Fever risk in the ecuadorian Amazon.
Izurieta RO, Macaluso M, Watts DM, Tesh RB, Guerra B, Cruz LM, Galwankar S, Vermund SH. J Glob Infect Dis. 2009 Jan; 1(1):7-13.
Does restricted distribution limit access and coverage of yellow fever vaccine in the United States?
Emerg Infect Dis. 1998
Does restricted distribution limit access and coverage of yellow fever vaccine in the United States?
Monath TP, Giesberg JA, Fierros EG. Emerg Infect Dis. 1998 Oct-Dec; 4(4):698-702.
Genetic studies of flavivirus resistance in inbred strains derived from wild mice: evidence for a new resistance allele at the flavivirus resistance locus (Flv).
J Virol. 1993
Genetic studies of flavivirus resistance in inbred strains derived from wild mice: evidence for a new resistance allele at the flavivirus resistance locus (Flv).
Sangster MY, Heliams DB, MacKenzie JS, Shellam GR. J Virol. 1993 Jan; 67(1):340-7.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.